Cargando…
Inhaled prostacyclin analogues in COVID-19 associated acute respiratory distress syndrome: scientific rationale
BACKGROUND: COVID-19 associated acute respiratory distress syndrome (CARDS) is a severe form of SARS CoV-2 infection and affects about 15–30% of hospitalized patients with a high mortality rate. Growing research and data suggest several available drugs with appropriate pharmacological effects to tre...
Autores principales: | Mulia, Eka Prasetya Budi, Luke, Kevin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443914/ https://www.ncbi.nlm.nih.gov/pubmed/34529182 http://dx.doi.org/10.1186/s43044-021-00208-y |
Ejemplares similares
-
Comparison of inhaled milrinone, nitric oxide and prostacyclin in acute respiratory distress syndrome
por: Albert, Martin, et al.
Publicado: (2017) -
Inhaled Prostacyclins for Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis
por: Torbic, Heather, et al.
Publicado: (2023) -
Inhaled prostacyclin therapy in the acute respiratory distress syndrome: a randomized controlled multicenter trial
por: Haeberle, Helene A., et al.
Publicado: (2023) -
Atrial Function Assessment in High-Risk Hypertrophic Cardiomyopathy
por: Mulia, Eka Prasetya Budi, et al.
Publicado: (2023) -
Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019
por: Villar, Jesús, et al.
Publicado: (2020)